IP Verse

E R Squibb & Sons competitive analysis

Latest patents of E R Squibb & Sons opposed by its competitors

Explore E R Squibb & Sons's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3597216
Aug 24, 2022Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof5
EP2905030
Nov 6, 2019Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof1
EP2439273
Feb 27, 2019Human Monoclonal Antibodies To Programmed Death 1(Pd-1) And Methods For Treating Cancer Using Anti-Pd-1 Antibodies Alone Or In Combination With Other Immunotherapeutics2
EP2501822
Aug 16, 2017Methods For Enhanced Protein Production2
EP2480561
Jul 13, 2016Cation Exchange Chromatography2
EP2003960
Jun 10, 2015Transgenic Animals Expressing Chimeric Antibodies For Use In Preparing Human Antibodies2

Latest PTAB cases involving E R Squibb & Sons

Discover the latest PTAB cases involving E R Squibb & Sons, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing E R Squibb & Sons with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
E R SQUIBB & SONS - 15 - -
DF MP DRRIES FRANK MOLNIA & POHLMAN13 - - -
KRAUS & WEISERT98 - - -
REGENERON PHARMACEUTICALS55142932